Neutrophilic Dermatoses: An Update

American Journal of Clinical Dermatology

Volumn 15, Issue 5, 2014, Pages 413-423

  Alavi, Afsaneh ^a,e   Sajic, Dusan ^a   Cerci, Felipe B ^b   Ghazarian, Danny ^c   Rosenbach, Misha ^d   Jorizzo, Joseph ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ABDOMINAL PAIN; ABNORMAL URINE COMPOSITION; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTHRALGIA; ARTICLE; BEHCET DISEASE; BOWEL ASSOCIATED DERMATOSIS ARTHRITIS SYNDROME; CLINICAL FEATURE; COMPLEMENT DEPOSITION; CUTANEOUS SMALL VESSEL VASCULITIS; DERMATITIS; ECCHYMOSIS; ERYTHEMA NODOSUM; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOGLOBULIN DEPOSITION; JOINT SWELLING; LEUKOCYTOCLASTIC VASCULITIS; MELENA; MOTOR NEUROPATHY; MYALGIA; NEUTROPHIL; NEUTROPHILIC DERMATOSIS; PALISADED NEUTROPHILIC AND GRANULOMATOUS DERMATOSIS; PANNICULITIS; PAPULE; PATHOGENESIS; POLYARTHRITIS; PURPURA; PYODERMA GANGRENOSUM; RHEUMATOID NEUTROPHILIC DERMATITIS; SENSORY NEUROPATHY; SKIN EDEMA; SKIN INFILTRATE; SKIN MANIFESTATION; SMALL VESSEL VASCULITIS; SYSTEMATIC REVIEW; PATHOLOGY; PATHOPHYSIOLOGY; SKIN; SKIN DISEASES;

HUMANS; NEUTROPHILS; SKIN; SKIN DISEASES;

EID: 84918833514     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-014-0092-6     Document Type: Article

References (74)

1. Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol. 1988;19(6):983–1005.
2. Berk DR, Bayliss SJ. Neutrophilic dermatoses in children. Pediatr Dermatol. 2008;25(5):509–19.
3. Kinney MA, Jorizzo JL. Small-vessel vasculitis. Dermatol Ther. 2012;25(2):148–57.
4. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
5. Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45(1):3–13.
6. Sais G, Vidaller A, Jucgla A, Servitje O, Condom E, Peyri J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134(3):309–15.
7. Ekenstam E, Callen JP. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984;120(4):484–9.
8. Caucanas M, Heylen A, Rolland F, Muller G, Olemans C, Sass U, et al. Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet’s syndrome: the concept of neutrophilic disease. Int J Dermatol. 2013;52(10):1185–8.
9. Swerlick RA, Lawley TJ. Cutaneous vasculitis: its relationship to systemic disease. Med Clin N Am. 1989;73(5):1221–35.
10. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27(6):504–28.
11. Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Freour E, Josselin N, et al. Atypical cutaneous vasculitis under lapatinib. Eur J Dermatol. 2013;23(4):540–1.
12. Novoa RA, Honda K, Koon HB, Gerstenblith MR. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol. 2012;67(6):e271–2.
13. Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996–2009. J Am Acad Dermatol. 2012;66(2):e55–65.
14. Ingraffea A, Donohue K, Wilkel C, Falanga V. Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh. J Am Acad Dermatol. 2007;56(5 Suppl):S124–6.
15. Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Henoch-Schonlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol. 2012;92(4):388–92.
16. Lever WF, Schaumburg-Lever S. Histopathology of the skin. Philadelphia: JB Lippincott; 1990.
17. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis: serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Arch Dermatol. 1990;126(1):69–72.
18. Bahrami S, Malone JC, Webb KG, Callen JP. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol. 2006;142(2):155–61.
19. Haeberle MT, Adams WB, Callen JP. Treatment of severe cutaneous small-vessel vasculitis with mycophenolate mofetil. Arch Dermatol. 2012;148(8):887–8.
20. Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87(8):739–45.
21. Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–64.
22. Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Curr Opin Hematol. 2013;20(1):26–35.
23. Paydas S. Sweet’s syndrome: a revisit for hematologists and oncologists. Crit Rev Oncol/Hematol. 2013;86(1):85–95.
24. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009;10(5):301–12.
25. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45(2):202–10.
26. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918–23.
27. Bonamigo RR, Razera F, Olm GS. Neutrophilic dermatoses: part I. An Bras Dermatol. 2011;86(1):11–25 (quiz 26–7).
28. Parsapour K, Reep MD, Gohar K, Shah V, Church A, Shwayder TA. Familial Sweet’s syndrome in 2 brothers, both seen in the first 2 weeks of life. J Am Acad Dermatol. 2003;49(1):132–8.
29. Razera F, Olm GS, Bonamigo RR. Neutrophilic dermatoses: part II. An Bras Dermatol. 2011;86(2):195–209 (quiz 210–1).
30. Vanourny J, Swick BL. Sweet syndrome with systemic inflammatory response syndrome. Arch Dermatol. 2012;148:969–70.
31. Heymann WR. Histiocytoid Sweet syndrome. J Am Acad Dermatol. 2009;61(4):693–4.
32. Requena L, Kutzner H, Palmedo G, Pascual M, Fernandez-Herrera J, Fraga J, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 2005;141(7):834–42.
33. Chavan RN, Cappel MA, Ketterling RP, Wada DA, Rochet NM, Knudson R, et al. Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. J Am Acad Dermatol. 2014;70(6):1021–7.
34. Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet’s syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013;42(5):1516–22.
35. Halawai A, Abiad F, Abbas O. Bariatric surgery and its effects on the skin and skin diseases. Obes Surg. 2013;23:408–13.
36. Dicken CH, Seehafer JR. Bowel bypass syndrome. Arch Dermatol. 1979;115:837–9.
37. Tu J, Chan JJ, Yu LL. Bowel bypass syndrome/bowel-associated dermatosis arthritis syndrome post laparoscopic gastric bypass surgery. Aust J Dermatol. 2011;52:e5–7.
38. Jorizzo JL, Apisarnthanarax P, Subrt P, Hebert AA, Henry JC, Raimer SS, et al. Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. Arch Int Med. 1983;143:457–61.
39. Slater GH, Kerlin P, Georghiou PR, Fielding GA. Bowel-associated dermatosis-arthritis syndrome after biliopancreatic diversion. Obes Surg. 2004;14:133–5.
40. Prpic-Massari L, Kastelan M, Brajac I, Cabrijan L, Zamolo G, Massari D. Bowel-associated dermatosis–arthritis syndrome in a patient with appendicitis. Med Sci Monit. 2007;13(8):CS97–100.
41. Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, Jimenez Hernandez C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9:241–5.
42. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet’s disease: from East to West. Clin Rheumatol. 2010;29:823–33.
43. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367–73.
44. Hatemi G, Seyahi E, Fresko I, Hamuryudan V. Behcet’s syndrome: a critical digest of the recent literature. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S80–9.
45. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmun Rev. 2012;11:699–704.
46. Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L. Anti-IL1 blocking agents in drug-resistant Behcet’s syndrome: our little case series. Clin Exp Rheum. Epub 2014 Apr 7.
47. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab: a case report. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S73–5.
48. Ozen S, Eroglu FK. Pediatric-onset Behcet disease. Curr Opin Rheumatol. 2013;25(5):636–42.
49. Wilmoth GJ, Perniciaro C. Cutaneous extravascular necrotizing granuloma (Winkelmann granuloma): confirmation of the association with systemic disease. J Am Acad Dermatol. 1996;34(5 Pt 1):753–9.
50. Kim SK, Park CK, Park YW, Jun JB, Yoo DH, Bae SC. Palisaded neutrophilic granulomatous dermatitis presenting as an unusual skin manifestation in a patient with Behcet’s disease. Scand J Rheumatol. 2005;34(4):324–7.
51. Hantash BM, Chiang D, Kohler S, Fiorentino D. Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis. J Am Acad Dermatol. 2008;58(4):661–4.
52. Kreuter A, Rose C, Zillikens D, Altmeyer P. Bullous rheumatoid neutrophilic dermatosis. J Am Acad Dermatol. 2005;52(5):916–8.
53. Fujio Y, Funakoshi T, Nakayama K, Amagai M, Ohyama M. Rheumatoid neutrophilic dermatosis with tense blister formation: a case report and review of the literature. Australas J Dermatol. 2012;.;55((1):):e12–4.
54. Sangueza OP, Caudell MD, Mengesha YM, Davis LS, Barnes CJ, Griffin JE, et al. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol. 2002;47(2):251–7.
55. Biswas A, Chittari K, van Gey Pittius D, Stephens M, Tan BB. Palisaded neutrophilic and granulomatous dermatitis in a child with type I diabetes mellitus and coeliac disease. Br J Dermatol. 2008;159(2):488–9.
56. Germanas JP, Mehrabi D, Carder KR. Palisaded neutrophilic granulomatous dermatitis in a 12-year-old girl with systemic lupus erythematosus. J Am Acad Dermatol. 2006;55(2 Suppl):S60–2.
57. Hunt RD, Hartman RD, Molho-Pessach V, Votava HJ, Schaffer JV. Palisaded neutrophilic and granulomatous dermatitis in an adolescent girl with perinuclear antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis and arthritis. J Am Acad Dermatol. 2012;67(4):e164–6.
58. Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130(10):1278–83.
59. Ergun T, Inanc N, Tuney D, Kotiloglu EK, Seckin D, Tetik C, et al. Skin manifestations of rheumatoid arthritis: a study of 215 Turkish patients. Int J Dermatol. 2008;47(9):894–902.
60. Bremner R, Simpson E, White CR, Morrison L, Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004;34(3):610–6.
61. Edgerton CC, Oglesby RJ, Bray D. Rheumatoid neutrophilic dermatitis. J Clin Rheum. 2006;12(5):266–7.
62. Yamamoto T, Ohkubo H, Nishioka K. Skin manifestations associated with rheumatoid arthritis. J Dermatol. 1995;22(5):324–9.
63. Bevin AA, Steger J, Mannino S. Rheumatoid neutrophilic dermatitis. Cutis. 2006;78(2):133–6.
64. Sanchez JL, Cruz A. Rheumatoid neutrophilic dermatitis. J Am Acad Dermatol. 1990;22(5 Pt 2):922–5.
65. Hirota TK, Keough GC, David-Bajar K, McCollough ML. Rheumatoid neutrophilic dermatitis. Cutis. 1997;60(4):203–5.
66. Setterfield JF, Shirlaw PJ, Challacombe SJ, Black MM. Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinaemia. Br J Dermatol. 2001;144(2):393–6.
67. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211.
68. Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol. 1972;106(6):901–5.
69. O’Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol. 1978;114(7):1061–4.
70. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.
71. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.
72. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203–17.
73. Hadi A, Lebwohl M. Clinical features of pyoderma gangrenosum and current diagnostic trends. J Am Acad Dermatol. 2011;64(5):950–4.
74. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347(18):1412–8.